Market research
CZO.V Ceapro Inc
V CAD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 689K
- P/E ratio
- Not available
- Analyst target
- 1.08
- Dividend yield
- Not available
- Beta
- 1.38
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA1499071076
- Market cap
- 689K
- P/E ratio
- Not available
- Analyst target
- 1.08
- Dividend yield
- Not available
- Beta
- 1.38
About
About Ceapro Inc
Ceapro Inc., a biotechnology company, engages in the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using proprietary technology, natural, and renewable resources in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of the technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also develops and commercializes active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. The company was incorporated in 1997 and is headquartered in Edmonton, Canada. As of June 3, 2024, Ceapro Inc. operates as a subsidiary of Aeterna Zentaris Inc.
Research context
Ceapro Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CZO.V discussion.
5 years, 6 months ago
Ceapro Inc is currently in a long term downtrend where the price is trading 2.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.
Ceapro Inc's total revenue rose by 19.5% to $3M since the same quarter in the previous year.
Its net income has increased by 285.1% to $192K since the same quarter in the previous year.
Finally, its free cash flow grew by 381.3% to $2M since the same quarter in the previous year.
Based on the above factors, Ceapro Inc gets an overall score of 4/5.